Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
88.07
-2.38 (-2.63%)
Jul 29, 2026, 4:00 PM EDT - Market closed
Oruka Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 49.52 | 46.94 | 61.58 | 37.43 | 42.45 | 53.36 |
Short-Term Investments | 339.31 | 290.11 | 314.07 | - | - | - |
Cash & Short-Term Investments | 388.83 | 337.04 | 375.65 | 37.43 | 42.45 | 53.36 |
Cash Growth | 11.38% | -10.28% | 903.58% | -11.81% | -20.45% | 8.74% |
Other Current Assets | 6.42 | 6.81 | 1.22 | 0.16 | 0.25 | 1.06 |
Total Current Assets | 395.25 | 343.86 | 376.87 | 37.59 | 42.7 | 54.42 |
Net Property, Plant & Equipment | 2.01 | 2.12 | 1.04 | 0.26 | 0.37 | 0.49 |
Long-Term Investments | 107.12 | 142.54 | 18.07 | - | - | - |
Other Long-Term Assets | 0.1 | 0.1 | 0.04 | 0.01 | 0.02 | 0.02 |
Total Assets | 504.48 | 488.62 | 396.02 | 37.86 | 43.09 | 54.92 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.66 | 4.16 | 3.46 | 0.36 | 0.33 | 1.12 |
Accrued Expenses | 9.29 | 10.59 | 3.35 | 0.28 | 0.17 | 2.38 |
Current Portion of Leases | 0.68 | 0.62 | 0.21 | - | - | - |
Other Current Liabilities | 3 | 0.01 | 6.02 | - | 0.63 | - |
Total Current Liabilities | 16.63 | 15.37 | 13.04 | 0.64 | 1.13 | 3.5 |
Long-Term Leases | 1.13 | 1.31 | 0.76 | 0.2 | 0.28 | 0.38 |
Total Long-Term Liabilities | 1.13 | 1.31 | 0.76 | 0.2 | 0.28 | 0.38 |
Total Liabilities | 17.76 | 16.69 | 13.8 | 0.84 | 1.41 | 3.88 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | 2.93 | 2.93 | 2.93 | - | - | - |
Common Stock | 0.05 | 0.05 | 0.04 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 705.2 | 657.56 | 463.02 | 225.75 | 225.06 | 224.51 |
Accumulated Other Comprehensive Income | -0.48 | 0.55 | -0.04 | - | - | - |
Retained Earnings | -220.98 | -189.16 | -83.72 | -188.74 | -183.4 | -173.48 |
Shareholders' Equity | 486.72 | 471.93 | 382.22 | 37.02 | 41.67 | 51.04 |
Total Liabilities & Equity | 504.48 | 488.62 | 396.02 | 37.86 | 43.09 | 54.92 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.81 | 1.93 | 0.97 | 0.2 | 0.28 | 0.38 |
Net Cash (Debt) | 387.02 | 335.11 | 374.68 | 37.23 | 42.17 | 52.98 |
Net Cash Growth | 11.17% | -10.56% | 906.47% | -11.71% | -20.41% | 8.87% |
Net Cash Per Share | 7.90 | 7.35 | 22.32 | 30.99 | 35.11 | 45.72 |
Book Value | 486.72 | 471.93 | 382.22 | 37.02 | 41.67 | 51.04 |
Book Value Per Share | 9.94 | 10.35 | 22.77 | 30.82 | 34.70 | 44.05 |
Tangible Book Value | 486.72 | 471.93 | 382.22 | 37.02 | 41.67 | 51.04 |
Tangible Book Value Per Share | 9.94 | 10.35 | 22.77 | 30.82 | 34.70 | 44.05 |